NYLIA 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NYLIA 7/7/7 (NYLIA 7/7/7).
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
| Metabolism | Ethinyl estradiol primarily via CYP3A4; norethindrone via reduction and sulfate conjugation. |
| Excretion | Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%) |
| Half-life | Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6 L/kg (range 0.4–0.8 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Oral: 75% (range 60–85%), with food decreasing absorption by 20%. |
| Onset of Action | Oral: 30–60 minutes for peak plasma concentration; therapeutic effect within 1–2 hours. |
| Duration of Action | 12–24 hours for symptom relief; sustained-release formulation extends to 24–36 hours. Duration may be shorter in patients with rapid metabolism. |
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment guidelines available; use caution in patients with renal impairment. Contraindicated in severe renal disease or renal failure due to potential hormonal metabolism alterations. |
| Liver impairment | Contraindicated in Child-Pugh class B or C cirrhosis or active liver disease. For mild hepatic impairment (Child-Pugh A), use caution and monitor for adverse effects; no specific dose reduction established. |
| Pediatric use | Not indicated for use in pediatric patients before menarche. For post-menarche adolescents, same dosing as adults; safety and efficacy established in females of reproductive age. |
| Geriatric use | Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke due to increased cardiovascular risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NYLIA 7/7/7 (NYLIA 7/7/7).
| Breastfeeding | Ethinyl estradiol and norethindrone are excreted in breast milk in small amounts. M/P ratio not well-established; estrogens may reduce milk production and quality. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Alternative contraception advised. |
| Teratogenic Risk | NYLIA 7/7/7 contains ethinyl estradiol and norethindrone. First trimester: Not associated with major teratogenic effects in humans based on epidemiological data. Second and third trimesters: Avoid use due to potential adverse effects such as fetal genital abnormalities (including hypospadias and feminization of male fetuses) and other adverse outcomes associated with sex hormone exposure during pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events; women over 35 who smoke should not use combination oral contraceptives.
| Serious Effects |
["Thrombophlebitis/thromboembolic disorders","Cerebrovascular/coronary artery disease","Known/suspected pregnancy","Undiagnosed abnormal genital bleeding","Known/suspected breast carcinoma","Hepatic adenoma/carcinoma","Jaundice/cholestatic jaundice with prior pill use","Hypersensitivity to any component","Heavy smoking (≥15 cigarettes/day) in women >35"]
| Precautions | ["Thrombotic disorders risk","Cerebrovascular disease","Myocardial infarction","Hepatic neoplasia","Gallbladder disease","Hypertension","Diabetes/glucose intolerance","Headache/migraine","Bleeding irregularities"] |
Loading safety data…
| Fetal Monitoring | Monitor for pregnancy status given potential risks. If inadvertent exposure occurs during pregnancy, ultrasound assessment for fetal anomalies may be considered. No specific routine maternal monitoring beyond standard prenatal care. |
| Fertility Effects | NYLIA 7/7/7 suppresses ovulation and is used as contraception. After discontinuation, return to fertility may be delayed by 1-2 cycles due residual hormonal effects, but no permanent impairment of female fertility has been demonstrated. |